NovalGen’s first pipeline product is a proprietary first in class bispecific T cell engager therapies that can safely harness the immune system to fight a wide range of cancers.
Developing a first-in-class autoregulation technology to create safer drugs
We are changing the paradigm of cancer therapy with our immunotherapy technology. Our focus is on the next generation of bispecific antibody technology to generate transformative outcomes in patients.
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.